We’ll see this week if the public markets’ love affair with biotech unicorns is still running hot — or not
Can another mRNA specialist capture the attention of public investors and maintain the sector’s rep for hosting super-sized unicorn valuations?
We’ll find out later this week as BioNTech out of Germany steers an offering intended to generate more than $250 million in cash with a valuation of $4.45 billion to its credit. They’ve been in business for the last 11 years, backed by the billionaire Strüngmann brothers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.